- Cardiovascular Risk/Epidemiology
- Cardiovascular Disease & Diabetes Statistics in Korea: Nationwide Data 2010 to 2019
-
Jin Hwa Kim, Junyeop Lee, Kyungdo Han, Jae-Taek Kim, Hyuk-Sang Kwon, on Behalf of the Diabetic Vascular Disease Research Group of the Korean Diabetes Association
-
Diabetes Metab J. 2024;48(6):1084-1092. Published online November 21, 2024
-
DOI: https://doi.org/10.4093/dmj.2024.0275
-
-
 Abstract
 PDF Supplementary Material PubReader  ePub
- Background
This study aimed to provide updated insights into the incidence and management of cardiovascular disease (CVD) in Korean adults with diabetes.
Methods
Using data from the Korean National Health Insurance Service and Korea National Health and Nutrition Examination Survey, we analyzed the representative national estimates of CVD in adults with diabetes.
Results
The age- and sex-standardized incidence rate of ischemic heart disease (IHD), ischemic stroke, and peripheral artery disease (PAD) decreased from 2010 to 2019 in individuals with type 2 diabetes mellitus (T2DM). However, an increase in the incidence of heart failure (HF) was observed during the same period. Only 4.96% of adults with diabetes and CVD achieved optimal control of all three risk factors (glycemic levels, blood pressure, and lipid control). Additionally, high-intensity statin treatment rates were 8.84% and 9.15% in individuals with IHD and ischemic stroke, respectively. Treatment with a sodium-glucose cotransporter-2 inhibitor (SGLT2i) or a glucagon-like peptide-1 receptor agonist (GLP-1RA) was relatively low in 2019, with only 11.87%, 7.10%, and 11.05% of individuals with IHD, ischemic stroke, and HF, respectively, receiving SGLT2i treatment. Furthermore, only 1.08%, 0.79%, and 1.06% of patients with IHD, ischemic stroke, and HF, respectively, were treated with GLP-1RA.
Conclusion
The incidence of most CVD (IHD, ischemic stroke, and PAD) decreased between 2010 and 2019, whereas the incidence of HF increased. The overall use of high-intensity statins, SGLT2i, and GLP-1RA remained low among individuals with T2DM and CVD.
- Drug/Regimen
- Efficacy and Safety of Treatment with Quadruple Oral Hypoglycemic Agents in Uncontrolled Type 2 Diabetes Mellitus: A Multi-Center, Retrospective, Observational Study
-
Jun Sung Moon, Sunghwan Suh, Sang Soo Kim, Heung Yong Jin, Jeong Mi Kim, Min Hee Jang, Kyung Ae Lee, Ju Hyung Lee, Seung Min Chung, Young Sang Lyu, Jin Hwa Kim, Sang Yong Kim, Jung Eun Jang, Tae Nyun Kim, Sung Woo Kim, Eonju Jeon, Nan Hee Cho, Mi-Kyung Kim, Hye Soon Kim, Il Seong Nam-Goong, Eun Sook Kim, Jin Ook Chung, Dong-Hyeok Cho, Chang Won Lee, Young Il Kim, Dong Jin Chung, Kyu Chang Won, In Joo Kim, Tae Sun Park, Duk Kyu Kim, Hosang Shon
-
Diabetes Metab J. 2021;45(5):675-683. Published online August 12, 2020
-
DOI: https://doi.org/10.4093/dmj.2020.0107
-
-
36,984
View
-
391
Download
-
10
Web of Science
-
7
Crossref
-
 Graphical Abstract
Abstract
PDFSupplementary MaterialPubReader ePub
 -
Background
Only few studies have shown the efficacy and safety of glucose-control strategies using the quadruple drug combination. Therefore, the aim of the present study was to investigate the usefulness of the quadruple combination therapy with oral hypoglycemic agents (OHAs) in patients with uncontrolled type 2 diabetes mellitus (T2DM).
Methods
From March 2014 to December 2018, data of patients with T2DM, who were treated with quadruple hypoglycemic medications for over 12 months in 11 hospitals in South Korea, were reviewed retrospectively. We compared glycosylated hemoglobin (HbA1c) levels before and 12 months after quadruple treatment with OHAs. The safety, maintenance rate, and therapeutic patterns after failure of the quadruple therapy were also evaluated.
Results
In total, 357 patients were enrolled for quadruple OHA therapy, and the baseline HbA1c level was 9.0%±1.3% (74.9±14.1 mmol/mol). After 12 months, 270 patients (75.6%) adhered to the quadruple therapy and HbA1c was significantly reduced from 8.9%±1.2% to 7.8%±1.3% (mean change, −1.1%±1.2%; P<0.001). The number of patients with HbA1c <7% increased significantly from 5 to 68 (P<0.005). In addition, lipid profiles and liver enzyme levels were also improved whereas no changes in body weight. There was no significant safety issue in patients treated with quadruple OHA therapy.
Conclusion
This study shows the therapeutic efficacy of the quadruple OHA regimen T2DM and demonstrates that it can be an option for the management of T2DM patients who cannot use insulin or reject injectable therapy.
-
Citations
Citations to this article as recorded by  - Estimating Type 2 Diabetes Prevalence: A Model of Drug Consumption Data
Rita Oliveira, Matilde Monteiro-Soares, José Pedro Guerreiro, Rúben Pereira, António Teixeira-Rodrigues
Pharmacy.2024; 12(1): 18. CrossRef - Disease burden and symptom management in type 2 diabetic patients: A phenomenological study
Sevgi Demir Çam, Sevda Uzun
Public Health Nursing.2024; 41(6): 1291. CrossRef - Comparing dual oral agents plus insulin vs. Triple oral agents in uncontrolled type II diabetes: A pilot study
Nadia Gul, Inayat Ur Rehman, Yasar shah, Arbab Muhammad Ali, Zahid Ali, Omer Shehzad, Khang Wen Goh, Long Chiau Ming, Amal K. Suleiman, Nimesh Lageju
PLOS ONE.2024; 19(11): e0311435. CrossRef - Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study
Kyung-Soo Kim, Kyung Ah Han, Tae Nyun Kim, Cheol-Young Park, Jung Hwan Park, Sang Yong Kim, Yong Hyun Kim, Kee Ho Song, Eun Seok Kang, Chul Sik Kim, Gwanpyo Koh, Jun Goo Kang, Mi Kyung Kim, Ji Min Han, Nan Hee Kim, Ji Oh Mok, Jae Hyuk Lee, Soo Lim, Sang S
Diabetes & Metabolism.2023; 49(4): 101440. CrossRef - Effectiveness and safety of teneligliptin added to patients with type 2 diabetes inadequately controlled by oral triple combination therapy: A multicentre, randomized, double‐blind, and placebo‐controlled study
Minyoung Lee, Woo‐je Lee, Jae Hyeon Kim, Byung‐Wan Lee
Diabetes, Obesity and Metabolism.2022; 24(6): 1105. CrossRef - A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study
Soree Ryang, Sang Soo Kim, Ji Cheol Bae, Ji Min Han, Su Kyoung Kwon, Young Il Kim, Il Seong Nam‐Goong, Eun Sook Kim, Mi‐kyung Kim, Chang Won Lee, Soyeon Yoo, Gwanpyo Koh, Min Jeong Kwon, Jeong Hyun Park, In Joo Kim
Diabetes, Obesity and Metabolism.2022; 24(9): 1800. CrossRef - Glycaemic control with add‐on thiazolidinedione or a sodium‐glucose co‐transporter‐2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: A 24‐week, randomized controlled trial
Jaehyun Bae, Ji Hye Huh, Minyoung Lee, Yong‐Ho Lee, Byung‐Wan Lee
Diabetes, Obesity and Metabolism.2021; 23(2): 609. CrossRef
- Technology/Device
- The Potential Role of MicroRNA in Diabetic Cardiomyopathy
-
Jin Hwa Kim
-
Diabetes Metab J. 2020;44(1):54-55. Published online February 21, 2020
-
DOI: https://doi.org/10.4093/dmj.2020.0019
-
-
4,334
View
-
76
Download
-
2
Web of Science
-
2
Crossref
-
PDFPubReader
-
Citations
Citations to this article as recorded by - What is the impact of ferroptosis on diabetic cardiomyopathy: a systematic review
Xiaokun Lou, Yuanyuan Zhang, Junfeng Guo, Lina Gao, Yingying Ding, Xinyu Zhuo, Qingqing Lei, Jing Bian, Rumei Lei, Wenyan Gong, Xingwei Zhang, Qibin Jiao
Heart Failure Reviews.2023; 29(1): 1. CrossRef - MiR-29a regulates cardiomyocyte apoptosis by targeting Bak1 in diabetic cardiomyopathy
Xiaoyan Wang, Zhitao Zhang, Mei Wang
The Journal of Biochemistry.2022; 171(6): 663. CrossRef
- Letter: Increased Serum Angiopoietin-Like 6 Ahead of Metabolic Syndrome in a Prospective Cohort Study (Diabetes Metab J 2019;43:521-9)
-
Jin Hwa Kim
-
Diabetes Metab J. 2019;43(5):727-728. Published online October 24, 2019
-
DOI: https://doi.org/10.4093/dmj.2019.0172
-
-
3,953
View
-
35
Download
-
1
Web of Science
-
1
Crossref
-
PDFPubReader
-
Citations
Citations to this article as recorded by - Angiopoietin-like proteins in atherosclerosis
Yi-Zhang Liu, Chi Zhang, Jie-Feng Jiang, Zhe-Bin Cheng, Zheng-Yang Zhou, Mu-Yao Tang, Jia-Xiang Sun, Liang Huang
Clinica Chimica Acta.2021; 521: 19. CrossRef
- Letter: Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome (Diabetes Metab J 2018;42:207-14)
-
Jin Hwa Kim
-
Diabetes Metab J. 2018;42(4):348-349. Published online August 21, 2018
-
DOI: https://doi.org/10.4093/dmj.2018.0135
-
-
3,905
View
-
44
Download
-
1
Crossref
-
PDFPubReader
-
Citations
Citations to this article as recorded by -
PCSK9 gene participates in the development of primary dyslipidemias
D Matías-Pérez, AD Pérez-Santiago, MA Sánchez Medina, JJ Alpuche Osorno, IA García-Montalvo
Balkan Journal of Medical Genetics.2021; 24(1): 5. CrossRef
- Clinical Diabetes & Therapeutics
- Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
-
Hyun Jin Kim, Seok O Park, Seung-Hyun Ko, Sang Youl Rhee, Kyu-Yeon Hur, Nan-Hee Kim, Min Kyong Moon, Byung-Wan Lee, Jin Hwa Kim, Kyung Mook Choi
-
Diabetes Metab J. 2017;41(6):423-429. Published online December 19, 2017
-
DOI: https://doi.org/10.4093/dmj.2017.41.6.423
-
-
6,702
View
-
80
Download
-
5
Web of Science
-
6
Crossref
-
Abstract
PDFPubReader
The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The cardiovascular safety of GLP-1RAs has been assessed in several randomized clinical trials and systematic reviews. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA. -
Citations
Citations to this article as recorded by - Anti-inflammatory effect of glucagon-like Peptide-1 receptor agonist on the neurosensory retina in an acute optic nerve injury rat model
Yeon Woong Chung, Ji Young Lee, Hyun Hee Ju, Jin A. Choi
European Journal of Pharmacology.2022; 933: 175269. CrossRef - Diabetes Risk Data Mining Method Based on Electronic Medical Record Analysis
Yang Liu, Zhaoxiang Yu, Yunlong Yang, Zhihan Lv
Journal of Healthcare Engineering.2021; 2021: 1. CrossRef - Paradigm Shift for the Treatment of Type 2 Diabetes Mellitus in Patients with Cardiovascular Disease: Cardiologist's Perspective
Doo Soo Jeon
Cardiovascular Prevention and Pharmacotherapy.2020; 2(1): 11. CrossRef - The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia
Ju-Ming Lu
Advances in Therapy.2019; 36(4): 798. CrossRef - A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes
Irene Romera, Ana Cebrián-Cuenca, Fernando Álvarez-Guisasola, Fernando Gomez-Peralta, Jesús Reviriego
Diabetes Therapy.2019; 10(1): 5. CrossRef - Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
Hyun Jin Kim
The Journal of Korean Diabetes.2018; 19(1): 35. CrossRef
- Clinical Diabetes & Therapeutics
- Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association
-
Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
-
Diabetes Metab J. 2017;41(5):337-348. Published online October 17, 2017
-
DOI: https://doi.org/10.4093/dmj.2017.41.5.337
-
-
8,235
View
-
86
Download
-
39
Web of Science
-
46
Crossref
-
Abstract
PDFPubReader
In 2017, the Korean Diabetes Association (KDA) published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). The KDA regularly updates its Clinical Practice Guidelines, but since the last update in 2015, many results from clinical trials have been introduced, and domestic data from studies performed in Korean patients with T2DM have been published. Recently, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations. Additionally, new data from clinical trials using dipeptidyl peptidase 4 inhibitors and thiazolidinediones in Korean patients with T2DM were added. Following a systematic review and assessment of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the use of antihyperglycemic agents and revised the treatment algorithm for Korean adult patients with T2DM. -
Citations
Citations to this article as recorded by
- Clinical Diabetes & Therapeutics
- Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus
-
Min Kyong Moon, Kyu-Yeon Hur, Seung-Hyun Ko, Seok-O Park, Byung-Wan Lee, Jin Hwa Kim, Sang Youl Rhee, Hyun Jin Kim, Kyung Mook Choi, Nan-Hee Kim
-
Diabetes Metab J. 2017;41(5):357-366. Published online October 24, 2017
-
DOI: https://doi.org/10.4093/dmj.2017.41.5.357
-
-
8,977
View
-
192
Download
-
20
Web of Science
-
18
Crossref
-
Abstract
PDFPubReader
The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus (T2DM). In combination therapy of oral hypoglycemic agents (OHAs), general recommendations were not changed from those of the 2015 KDA guidelines. The Committee on Clinical Practice Guidelines of the KDA has extensively reviewed and discussed the results of meta-analyses and systematic reviews of effectiveness and safety of OHAs and many clinical trials on Korean patients with T2DM for the update of guidelines. All OHAs were effective when added to metformin or metformin and sulfonylurea, although the effects of each agent on body weight and hypoglycemia were different. Therefore, selection of a second agent as a metformin add-on therapy or third agent as a metformin and sulfonylurea add-on therapy should be based on the patient's clinical characteristics and the efficacy, side effects, mechanism of action, risk of hypoglycemia, effect on body weight, patient preference, and combined comorbidity. In this review, we address the results of meta-analyses and systematic reviews, comparing the effectiveness and safety among OHAs. It will help to choose the appropriate drug for an individual patient with T2DM. -
Citations
Citations to this article as recorded by - Unveiling the potential of prodrug and drug-conjugate strategies in treatment of diabetes mellitus and its complications
Neha V. Bhilare, Rushikesh Shedge, Prashant M. Tambe, Ajinkya More
Medicinal Chemistry Research.2024; 33(3): 337. CrossRef - Regional Heterogeneity of the Results of Glucagon-Like Peptide 1 Receptor Agonist Trials in Type 2 Diabetes: A Reanalysis of Individual Participant Data
Ariane Jullien, Clément Jambon-Barbara, Jean-Luc Cracowski, Brian L. Claggett, Anne-Laure Borel, Charles Khouri, Matthieu Roustit
Diabetes Care.2024; 47(11): 1949. CrossRef - Advances in structure-hypoglycemic activity relationship and mechanisms of berry polysaccharides
Su Jiang-Peng, Fang Jia-Qin, Liu Chuang, Liu Shou-Ping, Chen Chun, Tan Chin-Ping, Wang Ping-Ping, Peng Yun-Ping, Fu Xiong
Food Bioscience.2024; 62: 105472. CrossRef - Bridging the Gap Between Diabetes and Cardiovascular Disease: A Comparative Review of Different Glucagon-Like Peptide-1 (GLP-1) Agonists: Efficacy, Safety, and Patient Outcomes
Feras A Alghamdi, Hussein A Alshegifi , Reema S Alhuthayli , Turki Helal, Turki A Huwait, Turki Alharbi, Abdulrahman F Akbar, Wejdan Alshehri, Sultan M AlSheikh
Cureus.2024;[Epub] CrossRef - Simultaneous Estimation of Repaglinide and Voglibose in Newly Approved Fixed-Dose Combination by using UFLC: Application to ICH Q14 Concept and Comparative Method Greenness Assessment
S.S. Panda, P.C. Rauta, V.S. Pulusu, S. Sahu, B.B. Dash
Asian Journal of Chemistry.2023; 35(4): 887. CrossRef - Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach
Ashok Kumar Das, Banshi Saboo, Rajeev Chawla, S. R. Aravind, Rajesh Rajput, Awadhesh K. Singh, J. J. Mukherjee, Ashok Jhingan, Parag Shah, Vaishali Deshmukh, Shailaja Kale, Shalini Jaggi, G. R. Sridhar, Rajnish Dhediya, Kumar Gaurav
International Journal of Diabetes in Developing Countries.2023; 43(6): 856. CrossRef - The Gut Microbiome, Metformin, and Aging
Sri Nitya Reddy Induri, Payalben Kansara, Scott C. Thomas, Fangxi Xu, Deepak Saxena, Xin Li
Annual Review of Pharmacology and Toxicology.2022; 62(1): 85. CrossRef - Role of resveratrol supplementation in regulation of glucose hemostasis, inflammation and oxidative stress in patients with diabetes mellitus type 2: A randomized, placebo-controlled trial
Wajiha Mahjabeen, Dilshad Ahmed Khan, Shakil Ahmed Mirza
Complementary Therapies in Medicine.2022; 66: 102819. CrossRef - Letrozole: Pharmacology, toxicity and potential therapeutic effects
Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, Dhanushya Nagarajan, Vibhaa K K, Anagha V, Joshua Paul P, Tharani Priya T, Rituraj Chakraborty, Kaviyarasi Renu, Abhijit Dey, Balachandar Vellingiri, Abilash Valsala Gopalakrishnan
Life Sciences.2022; 310: 121074. CrossRef - Increasing Individual Target Glucose Levels to Prevent Hypoglycemia in Patients with Diabetes
Juyoung Shin, Hyunah Kim, Hun-Sung Kim, Churlmin Kim, Whan-Seok Choi
Korean Journal of Family Medicine.2021; 42(4): 269. CrossRef - Treatment intensification in type 2 diabetes management after the failure of two oral hypoglycemic agents: A non‐interventional comparative study
Sirajudeen Shaik Alavudeen, Sultan M. Alshahrani, Easwaran Vigneshwaran, Noohu Abdulla Khan, Javid I. Mir, Abubakr T. M. Hussein
International Journal of Clinical Practice.2021;[Epub] CrossRef - Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus
Antonios Kousaxidis, Anthi Petrou, Vasiliki Lavrentaki, Maria Fesatidou, Ioannis Nicolaou, Athina Geronikaki
European Journal of Medicinal Chemistry.2020; 207: 112742. CrossRef - Letter: Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2019;43;276-86)
Hannah Seok, Tae Seo Sohn
Diabetes & Metabolism Journal.2019; 43(4): 545. CrossRef - A Survey of the Structures of US FDA Approved Combination Drugs
Pradipta Das, Michael D. Delost, Munaum H. Qureshi, David T. Smith, Jon T. Njardarson
Journal of Medicinal Chemistry.2019; 62(9): 4265. CrossRef - Experimental design methodology for optimization and robustness determination in ion pair RP-HPLC method development: Application for the simultaneous determination of metformin hydrochloride, alogliptin benzoate and repaglinide in tablets
Marianne A. Mahrouse, Nesrine T. Lamie
Microchemical Journal.2019; 147: 691. CrossRef - The influence of diabetes and antidiabetic medications on the risk of pancreatic cancer: a nationwide population-based study in Korea
Da Young Lee, Ji Hee Yu, Sanghyun Park, Kyungdo Han, Nam Hoon Kim, Hye Jin Yoo, Kyung Mook Choi, Sei Hyun Baik, Nan Hee Kim, Ji A. Seo
Scientific Reports.2018;[Epub] CrossRef - Effect of Lifestyle Modification and Oral Anti-Diabetic Drugs on Metabolic Parameters in Recently Diagnosed Patientswith Uncomplicated Type 2 Diabetes Mellitus in Eastern India
Nikhilesh Pradhan, Sidhartha Das, Anoj Kumar Baliarsinha, Ashirbad Parhi, Bijan Patnaik, Pramod Kumar Rout
Journal of Diabetes Mellitus.2018; 08(02): 9. CrossRef - Failure of monotherapy in clinical practice in patients with type 2 diabetes: The Korean National Diabetes Program
Ja Young Jeon, Soo Jin Lee, Sieun Lee, Soo Jin Kim, Seung Jin Han, Hae Jin Kim, Dae Jung Kim, Young Seol Kim, Jeong Taek Woo, Kyu Jeung Ahn, Moonsuk Nam, Sei Hyun Baik, Yongsoo Park, Kwan‐Woo Lee
Journal of Diabetes Investigation.2018; 9(5): 1144. CrossRef
- Clinical Diabetes & Therapeutics
- Monotherapy in Patients with Type 2 Diabetes Mellitus
-
Sang Youl Rhee, Hyun Jin Kim, Seung-Hyun Ko, Kyu-Yeon Hur, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Kyung Mook Choi, Jin Hwa Kim
-
Diabetes Metab J. 2017;41(5):349-356. Published online October 19, 2017
-
DOI: https://doi.org/10.4093/dmj.2017.41.5.349
-
-
6,705
View
-
90
Download
-
15
Web of Science
-
17
Crossref
-
Abstract
PDFPubReader
In order to improve the quality of life and to prevent chronic complications related to diabetes mellitus, intensive lifestyle modification and proper medication are needed from the early stage of diagnosis of type 2 diabetes mellitus (T2DM). When using the first medication for diabetic patients, the appropriate treatment should be selected considering the clinical characteristics of the patient, efficacy of the drug, side effects, and cost. In general, the use of metformin as the first treatment for oral hypoglycemic monotherapy is recommended because of its excellent blood glucose-lowering effect, relatively low side effects, long-term proven safety, low risk of hypoglycemia, and low weight gain. If metformin is difficult to use as a first-line treatment, other appropriate medications should be selected in view of the clinical situation. If the goal of achieving glycemic control is not achieved by monotherapy, a combination therapy with different mechanisms of action should be initiated promptly. -
Citations
Citations to this article as recorded by - Brazil nut (Bertholletia excelsa) and metformin abrogate cardiac complication in fructose/STZ-induced type 2 diabetic rats by attenuating oxidative stress and modulating the MAPK-mTOR/NFkB/IL-10 signaling pathways
Zhenzuo Li, Baolan Wang, Dongfang Bai, Li Zhang
Food & Nutrition Research.2024;[Epub] CrossRef - Metformin and vitamin D combination therapy ameliorates type 2 diabetes mellitus-induced renal injury in male Wistar rats
Halimat Amin Abdulrahim, Adeyemi Fatai Odetayo, Emmanuel Aduragbemi Owootori, Joshua Damrah Bulus, Fatimoh Bolanle Jimoh, Emmanuel Oluwamuyiwa Gabriel, Iyanu Feranmi Odiete, Luqman Aribidesi Olayaki
Naunyn-Schmiedeberg's Archives of Pharmacology.2024;[Epub] CrossRef - A comparison of the Anti-diabetic Potential of Magnetized Water, Metformin, and Their Combination in A Rat Model of Type II Diabetes
Alaa H. Sayed, Amira S. Ahmed, Mahmoud Hozayn, Ola A. M. Mohawed, Hanaa H. Ahmed, Rehab S. Abohashem
Biomedical and Pharmacology Journal.2024; 17(3): 1575. CrossRef - Major adverse cardiovascular events’ reduction and their association with glucose‐lowering medications and glycemic control among patients with type 2 diabetes: A retrospective cohort study using electronic health records
Haowen Hsu, Paul Thomas Kocis, Ariana Pichardo‐Lowden, Wenke Hwang
Journal of Diabetes.2024;[Epub] CrossRef - Comparing dual oral agents plus insulin vs. Triple oral agents in uncontrolled type II diabetes: A pilot study
Nadia Gul, Inayat Ur Rehman, Yasar shah, Arbab Muhammad Ali, Zahid Ali, Omer Shehzad, Khang Wen Goh, Long Chiau Ming, Amal K. Suleiman, Nimesh Lageju
PLOS ONE.2024; 19(11): e0311435. CrossRef - Diabetic Patients with COVID-19 Complications: Insights into Prevalence,
Prognosis, Combination Medications, and Underlying Mechanisms
Pranay Wal, Jyotsana Dwivedi, Ankita Wal, Shivangi Kushwaha
Current Diabetes Reviews.2023;[Epub] CrossRef - Increasing Individual Target Glucose Levels to Prevent Hypoglycemia in Patients with Diabetes
Juyoung Shin, Hyunah Kim, Hun-Sung Kim, Churlmin Kim, Whan-Seok Choi
Korean Journal of Family Medicine.2021; 42(4): 269. CrossRef - Synthesis, antidiabetic activity and molecular docking study of rhodanine-substitued spirooxindole pyrrolidine derivatives as novel α-amylase inhibitors
Amani Toumi, Sarra Boudriga, Khaled Hamden, Mansour Sobeh, Mohammed Cheurfa, Moheddine Askri, Michael Knorr, Carsten Strohmann, Lukas Brieger
Bioorganic Chemistry.2021; 106: 104507. CrossRef - Clinical Impact of Combination Therapy in Diabetic Neuropathy and Nephropathy
Harmeet Kaur, Arvinder Kaur, Pankaj Kumar Prashar, Anamika Gautam, Ankita Sood, Sachin Kumar Singh, Monica Gulati, Narendra Kumar Pandey, Bimlesh Kumar
Research Journal of Pharmacy and Technology.2021; : 3471. CrossRef - Type II diabetes mellitus: a review on recent drug based therapeutics
Santwana Padhi, Amit Kumar Nayak, Anindita Behera
Biomedicine & Pharmacotherapy.2020; 131: 110708. CrossRef - Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open‐label, active‐controlled, 12‐week study (STABLE II study)
Soo Heon Kwak, You‐Cheol Hwang, Jong Chul Won, Ji Cheol Bae, Hyun Jin Kim, Sunghwan Suh, Eun Young Lee, Subin Lee, Sang‐Yong Kim, Jae Hyeon Kim
Diabetes, Obesity and Metabolism.2020; 22(2): 173. CrossRef - Metabolomics approach to identify the active substances influencing the antidiabetic activity of Lagerstroemia species
Mun-Ock Kim, Su Ui Lee, Heung Joo Yuk, Hyun-Jae Jang, Jae-Won Lee, Eun-Bin Kwon, Jin-Hyub Paik, SangHo Choi, Adek Nizar, Tran The Bach, Kongmany Sydara, Hang Jin, So-Yeun Woo, Sei-Ryang Oh, Hyung Won Ryu
Journal of Functional Foods.2020; 64: 103684. CrossRef - Cardiometabolic diseases and active aging - polypharmacy in control
Adriana Nancy Medeiros dos Santos, Dulcineia Rebecca Cappelletti Nogueira, Beatriz Aparecida Ozello Gutierrez, Rosa Yuka Sato Chubaci, Caroline Ribeiro de Borja Oliveira
Revista Brasileira de Enfermagem.2020;[Epub] CrossRef - Anti-Diabetic Nephropathy Activities of Polysaccharides Obtained from Termitornyces albuminosus via Regulation of NF-κB Signaling in db/db Mice
Chang Yang, Qi Feng, Huan Liao, Xinlei Yu, Yang Liu, Di Wang
International Journal of Molecular Sciences.2019; 20(20): 5205. CrossRef - Specific PERK inhibitors enhanced glucose-stimulated insulin secretion in a mouse model of type 2 diabetes
Min Joo Kim, Mi Na Kim, Se Hee Min, Dong-Sik Ham, Ji-Won Kim, Kun-Ho Yoon, Kyong Soo Park, Hye Seung Jung
Metabolism.2019; 97: 87. CrossRef - A randomized, open‐label, multicentre, parallel‐controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral anti
Lixin Guo, Li Chen, Baocheng Chang, Liyong Yang, Yu Liu, Bo Feng
Diabetes, Obesity and Metabolism.2018; 20(12): 2740. CrossRef - Monotherapy in Type 2 Diabetes Mellitus Patients 2017: A Position Statement of the Korean Diabetes Association
Sang Youl Rhee
The Journal of Korean Diabetes.2018; 19(1): 15. CrossRef
- Clinical Diabetes & Therapeutics
- Insulin Therapy for Adult Patients with Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association, 2017
-
Byung-Wan Lee, Jin Hwa Kim, Seung-Hyun Ko, Kyu-Yeon Hur, Nan-Hee Kim, Sang Youl Rhee, Hyun Jin Kim, Min Kyong Moon, Seok-O Park, Kyung Mook Choi
-
Diabetes Metab J. 2017;41(5):367-373. Published online October 24, 2017
-
DOI: https://doi.org/10.4093/dmj.2017.41.5.367
-
-
8,995
View
-
264
Download
-
10
Web of Science
-
11
Crossref
-
Abstract
PDFPubReader
The Korean Diabetes Association (KDA) has regularly updated its Clinical Practice Guidelines. In 2017, the KDA published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). Growing evidence from new multinational clinical trials using novel and traditional insulin analogues has also been accumulated. Following global trends, many results of clinical trials, especially concerning the clinical efficacy and safety of insulin therapy, have been published about Korean patients with T2DM. After a systematic search of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the initiation, choice, and intensification of insulin and created an insulin treatment algorithm for the first time to guide physicians caring for adult Korean patients with T2DM. -
Citations
Citations to this article as recorded by - Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study
Eun-Gyoung Hong, Kyung-Wan Min, Jung Soo Lim, Kyu-Jeung Ahn, Chul Woo Ahn, Jae-Myung Yu, Hye Soon Kim, Hyun Jin Kim, Won Kim, Dong Han Kim, Hak Chul Jang
Advances in Therapy.2024; 41(5): 1967. CrossRef - Exploring Folklore Ecuadorian Medicinal Plants and Their Bioactive Components Focusing on Antidiabetic Potential: An Overview
Soham Bhattacharya, Neha Gupta, Adéla Flekalová, Salomé Gordillo-Alarcón, Viviana Espinel-Jara, Eloy Fernández-Cusimamani
Plants.2024; 13(11): 1436. CrossRef - 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association
Jun Sung Moon, Shinae Kang, Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Ji A Seo, Mee Kyoung Kim, Jeong Hyun Lim, Yoon Ju Song, Ye Seul Yang, Jae Hyeon Kim, You-Bin Lee, Junghyun Noh, Kyu Yeon Hur, Jong Suk Park, Sang
Diabetes & Metabolism Journal.2024; 48(4): 546. CrossRef - Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy
Youngsook Kim, Ji Hye Huh, Minyoung Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
Frontiers in Endocrinology.2022;[Epub] CrossRef - Increasing Individual Target Glucose Levels to Prevent Hypoglycemia in Patients with Diabetes
Juyoung Shin, Hyunah Kim, Hun-Sung Kim, Churlmin Kim, Whan-Seok Choi
Korean Journal of Family Medicine.2021; 42(4): 269. CrossRef - Effects of an actual insulin injection demonstration on insulin acceptance among patients with T2DM: a pragmatic randomized controlled trial
Atthayaporn Choomai, Apichai Wattanapisit, Orathai Tiangtam
Romanian Journal of Internal Medicine.2021; 59(2): 151. CrossRef - Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes
Han Na Jang, Ye Seul Yang, Seong Ok Lee, Tae Jung Oh, Bo Kyung Koo, Hye Seung Jung
Endocrinology and Metabolism.2019; 34(4): 382. CrossRef - Capacity and confidence building for general practitioners on optimum insulin use
Sanjay Kalra, Prasun Deb, KalyanK Gangopadhyay, Sunil Gupta, Abhay Ahluwalia
Journal of Family Medicine and Primary Care.2019; 8(10): 3096. CrossRef - Educational Strategies for Insulin Injection Therapy in Elderly Diabetic Patients
Eun Chong Shin
The Journal of Korean Diabetes.2018; 19(2): 101. CrossRef - Summary of Insulin Therapy for Adult Patients with Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association, 2017
Byung-Wan Lee
The Journal of Korean Diabetes.2018; 19(1): 31. CrossRef - New anti-diabetic agents
Doo-Man Kim
Journal of the Korean Medical Association.2017; 60(12): 992. CrossRef
- Response: Clinical Marker of Platelet Hyperreactivity in Diabetes Mellitus (Diabetes Metab J 2013;37:423-8)
-
Jin Hwa Kim, Hak Yeon Bae, Sang Yong Kim
-
Diabetes Metab J. 2014;38(2):160-161. Published online April 18, 2014
-
DOI: https://doi.org/10.4093/dmj.2014.38.2.160
-
-
3,780
View
-
34
Download
-
5
Web of Science
-
5
Crossref
-
PDFPubReader
-
Citations
Citations to this article as recorded by - The unique association between the level of plateletcrit and the prevalence of diabetic kidney disease: a cross-sectional study
Shuwu Wei, Xinyu Pan, Yao Xiao, Ruishuang Chen, Junping Wei
Frontiers in Endocrinology.2024;[Epub] CrossRef - Impact of Uncontrolled Diabetes Mellitus on Blood Cells Indices and Plasma Components in Patients Without Nephropathy
Hisham Ali Waggiallah, Hala Elsir Khair, Rania Saad Suliman, Humood Al Shmrany, Elturabi Elsayed Elkhider, Mudathir Mohamed Ahmed Eltayeb, Nermen Abdelftah Mohamed Ma, Yousif Mohammed Elmosaad
Pakistan Journal of Biological Sciences.2023; 26(5): 279. CrossRef - Effects of statin therapy on mean platelet volume in patients with risk of cardiovascular diseases: a systematic review and meta-analysis
Shuaifei Ji, Babo Zhang, Xianda Wang, Heng Shi, Lixin Yu, Xiaocheng Wang
Bioscience Reports.2019;[Epub] CrossRef - The relationship between mean platelet volume and diabetic retinopathy: a systematic review and meta-analysis
ShuaiFei Ji, Jie Zhang, XiuDe Fan, XiQiang Wang, XiaoNa Ning, BaBo Zhang, Heng Shi, Hong Yan
Diabetology & Metabolic Syndrome.2019;[Epub] CrossRef - Platelets volume indexes and cardiovascular risk factors
Thaís Resende Batista, Roberta Carvalho de Figueiredo, Danyelle Romana Alves Rios
Revista da Associação Médica Brasileira.2018; 64(6): 554. CrossRef
- Clinical Marker of Platelet Hyperreactivity in Diabetes Mellitus
-
Jin Hwa Kim, Hak Yeon Bae, Sang Yong Kim
-
Diabetes Metab J. 2013;37(6):423-428. Published online December 12, 2013
-
DOI: https://doi.org/10.4093/dmj.2013.37.6.423
-
-
5,386
View
-
77
Download
-
28
Crossref
-
Abstract
PDFPubReader
Atherothrombotic complications are important causes of morbidity and mortality in diabetic patients. Diabetes has been considered to be a prothrombotic status. Several factors contribute to the prothrombotic condition, such as increasing coagulation, impaired fibrinolysis, endothelial dysfunction, and platelet hyperreactivity. Among the factors that contribute to the prothrombotic status in diabetes, altered platelet function plays a crucial role. Although understanding platelet function abnormalities in diabetes still remains as a challenge, more attention should be focused on platelet function for effective management and the prediction of atherothrombotic events in diabetic patients. This review will provide an overview on the current status of knowledge of platelet function abnormalities and clinical marker of platelet hyperreactivity in patients with diabetes. -
Citations
Citations to this article as recorded by - Single nucleotide polymorphism rs7961894, platelet morphological parameters and lipid profile in children with type 1 diabetes: a potential relationship
Mahmoud A. El-Hawy, Shimaa Abdelsattar, Hanan M. Bedair, Doaa Z. Elsaady, Ahmed S. Abo Hola
European Journal of Pediatrics.2024; 183(10): 4385. CrossRef - Prediction of type 2 diabetes mellitus using hematological factors based on machine learning approaches: a cohort study analysis
Amin Mansoori, Toktam Sahranavard, Zeinab Sadat Hosseini, Sara Saffar Soflaei, Negar Emrani, Eisa Nazar, Melika Gharizadeh, Zahra Khorasanchi, Sohrab Effati, Mark Ghamsary, Gordon Ferns, Habibollah Esmaily, Majid Ghayour Mobarhan
Scientific Reports.2023;[Epub] CrossRef - Platelet P2Y1 receptor exhibits constitutive G protein signaling and β-arrestin 2 recruitment
Agnès Ribes, Cédric Garcia, Marie-Pierre Gratacap, Evi Kostenis, Laurent O. Martinez, Bernard Payrastre, Jean-Michel Sénard, Céline Galés, Véronique Pons
BMC Biology.2023;[Epub] CrossRef - Sex differences in the relationship between platelet count and type 2 diabetes risk in community‐dwelling adults: Longitudinal findings over 14 years
Eun Kyeong Yun, In‐Ho Seo, Hye Sun Lee, So‐Young Seol, Yong‐Jae Lee
Diabetes/Metabolism Research and Reviews.2023;[Epub] CrossRef - Platelet Glycoprotein-Ib (GPIb) May Serve as a Bridge between Type 2 Diabetes Mellitus (T2DM) and Atherosclerosis, Making It a Potential Target for Antiplatelet Agents in T2DM Patients
Muttia Amalia, Meidi Utami Puteri, Fadlina Chany Saputri, Rani Sauriasari, Bambang Widyantoro
Life.2023; 13(7): 1473. CrossRef - Effect of oral versus parenteral vitamin D3 supplementation on nuclear factor-κB and platelet aggregation in type 2 diabetic patients
Esraa Habiba, Samia Ali, Yehia Ghanem, Ola Sharaki, Wafaa Hewedy
Canadian Journal of Physiology and Pharmacology.2023; 101(11): 610. CrossRef - Characteristics of cerebral ischemic stroke based on moyamoya disease and atherosclerosis-associated intracranial arterial stenosis
Zhiying Chen, Xiaoqin Wu, Da Zhou, Shuling Shang, Yuchuan Ding, Xunming Ji, Ran Meng
Neurological Sciences.2022; 43(2): 1087. CrossRef - Basic Coagulation Profiles and Platelet Parameters Among Adult Type 1 and Type 2 Diabetes Patients at Dessie Referral Hospital, Northeast Ethiopia: Comparative Cross-Sectional Study
Hussen Ebrahim, Fikir Asrie, Zegeye Getaneh
Journal of Blood Medicine.2021; Volume 12: 33. CrossRef - Magnetic fields as a potential therapy for diabetic wounds based on animal experiments and clinical trials
Huanhuan Lv, Junyu Liu, Chenxiao Zhen, Yijia Wang, Yunpeng Wei, Weihao Ren, Peng Shang
Cell Proliferation.2021;[Epub] CrossRef - Diabetes and hypertension: Pivotal involvement of purinergic signaling
Karine Paula Reichert, Milagros Fanny Vera Castro, Charles Elias Assmann, Nathieli Bianchin Bottari, Vanessa Valéria Miron, Andréia Cardoso, Naiara Stefanello, Vera Maria Melchiors Morsch, Maria Rosa Chitolina Schetinger
Biomedicine & Pharmacotherapy.2021; 137: 111273. CrossRef - The hemostatic parameters in pregnant women with different types of diabetes mellitus
R. V. Kapustin, E. V. Kopteeva, O. N. Arzhanova, A. V. Tiselko, N. Е. Androsova, T. I. Oparina
Diabetes mellitus.2021; 24(3): 251. CrossRef - A study of activated platelet by flow cytometry in diabetic patients with peripheral arterial disease
Maisa A. Abdel Wahab, Shaymaa A. Mohammed, Inass H. Ahmad, Salwa I. Elshennawy, Sadek Mostafa
Al-Azhar Assiut Medical Journal.2021; 19(3): 395. CrossRef - Comparison of the progressive changes in hemogram parameters of normal glycemic and gestational diabetic patients throughout the first two trimesters and predictive ability of these indices for gestational diabetes mellitus
Pelin AYTAN, Seyran BOZKURT BABUŞ, Özde SAKARYA, Revan Sabri ÇİFTÇİ, Kasım AKAY, Hakan AYTAN
Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi.2020; 17(4): 533. CrossRef - A Pilot Study on the Effect of Anti-Thrombopoietin Antibody on Platelet Count in Patients with Type 2 Diabetes
Takuya Fukuda, Masahide Hamaguchi, Takafumi Osaka, Yoshitaka Hashimoto, Emi Ushigome, Mai Asano, Masahiro Yamazaki, Eriko Fukuda, Kei Yamaguchi, Koji Ogawa, Naoki Goshima, Michiaki Fukui
Molecules.2020; 25(7): 1667. CrossRef - Patient with diabetes after acute coronary event. How to improve forecast?
O. L. Barbarash
Medical alphabet.2019; 1(3): 6. CrossRef - Enhanced Platelet Sensitivity to IGF-1 in Patients with Type 2 Diabetes Mellitus
N. Gligorijevic, D. Robajac, O. Nedic
Biochemistry (Moscow).2019; 84(10): 1213. CrossRef - Comprehensive Quality Control of the Regenerative Therapy Using Platelet Concentrates: The Current Situation and Prospects in Japan
Tomoyuki Kawase, Kazuhiro Okuda
BioMed Research International.2018; 2018: 1. CrossRef - Changes in platelet morphology indices in relation to duration of disease and glycemic control in children with type 1 diabetes mellitus
Vybhav Venkatesh, Rakesh Kumar, Dinesh Kumar Varma, Prateek Bhatia, Jaivinder Yadav, Devi Dayal
Journal of Diabetes and its Complications.2018; 32(9): 833. CrossRef - Quantifying Platelet Margination in Diabetic Blood Flow
Hung-Yu Chang, Alireza Yazdani, Xuejin Li, Konstantinos A.A. Douglas, Christos S. Mantzoros, George Em Karniadakis
Biophysical Journal.2018; 115(7): 1371. CrossRef - Redox Proteomics and Platelet Activation: Understanding the Redox Proteome to Improve Platelet Quality for Transfusion
Giona Sonego, Mélanie Abonnenc, Jean-Daniel Tissot, Michel Prudent, Niels Lion
International Journal of Molecular Sciences.2017; 18(2): 387. CrossRef - Farnesoid X Receptor and Liver X Receptor Ligands Initiate Formation of Coated Platelets
Amanda J. Unsworth, Alexander P. Bye, Dionne S. Tannetta, Michael J.R. Desborough, Neline Kriek, Tanya Sage, Harriet E. Allan, Marilena Crescente, Parveen Yaqoob, Timothy D. Warner, Chris I. Jones, Jonathan M. Gibbins
Arteriosclerosis, Thrombosis, and Vascular Biology.2017; 37(8): 1482. CrossRef - Aspirin in the prevention of cardiovascular events in patients with diabetes
David S. H. Bell
Postgraduate Medicine.2016; 128(2): 180. CrossRef - ROLE OF NITRIC OXIDE METABOLITES WITHIN THE IMPACT OF THE SUB-TOXIC SUCCINAMIDES DOSES ON STATE OF HEMOSTASIS
I.А. Palagina, M.Y. Kudria, О.S. Lаlymеnkо
Fiziolohichnyĭ zhurnal.2016; 62(6): 34. CrossRef - Influence of genetic variations in platelet glycoproteins and eNOS in the development of arterial ischaemia of lower limbs in type 2 diabetes mellitus patients
Virginia Carvalhais, Ema Ruivães, Luis Bernardo Pina-Cabral, Bárbara Mesquita, Flávio Oliveira, Maria Céu Monteiro, Maria Begoña Criado
The Foot.2016; 29: 42. CrossRef - Circulating endothelial progenitor cells and angiogenic factors in diabetes complicated diabetic foot and without foot complications
Arleta Kulwas, Ewelina Drela, Wiesław Jundziłł, Barbara Góralczyk, Barbara Ruszkowska-Ciastek, Danuta Rość
Journal of Diabetes and its Complications.2015; 29(5): 686. CrossRef - Cerebrovascular diseases: perspectives of pathogenetic metabolic haemangiocorrective treatment
M. M. Tanashyan, O. V. Lagoda, K. V. Antonova
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2015; 115(9): 70. CrossRef - Letter: Clinical Marker of Platelet Hyperreactivity in Diabetes Mellitus (Diabetes Metab J2013;37:423-8)
Cengiz Beyan, Esin Beyan
Diabetes & Metabolism Journal.2014; 38(2): 158. CrossRef - Response: Clinical Marker of Platelet Hyperreactivity in Diabetes Mellitus (Diabetes Metab J2013;37:423-8)
Jin Hwa Kim, Hak Yeon Bae, Sang Yong Kim
Diabetes & Metabolism Journal.2014; 38(2): 160. CrossRef
|
KDA
